Kefeng Wang

1.8k total citations
43 papers, 1.2k citations indexed

About

Kefeng Wang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Kefeng Wang has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 30 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Kefeng Wang's work include Cancer-related molecular mechanisms research (20 papers), RNA modifications and cancer (16 papers) and Circular RNAs in diseases (15 papers). Kefeng Wang is often cited by papers focused on Cancer-related molecular mechanisms research (20 papers), RNA modifications and cancer (16 papers) and Circular RNAs in diseases (15 papers). Kefeng Wang collaborates with scholars based in China, United States and Taiwan. Kefeng Wang's co-authors include Xiang Fei, Chawnshang Chang, Yin Sun, Xia Wang, Manlong Qi, Tao Wei, Xia Wang, Jun Yang, Wei Jin and Yan Song and has published in prestigious journals such as International Journal of Cancer, Sensors and Actuators B Chemical and Molecular Cancer.

In The Last Decade

Kefeng Wang

40 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kefeng Wang China 20 1.0k 909 110 83 72 43 1.2k
Erhu Fang China 16 926 0.9× 664 0.7× 77 0.7× 107 1.3× 50 0.7× 29 1.1k
Zerong Cai China 10 1.0k 1.0× 750 0.8× 77 0.7× 125 1.5× 54 0.8× 25 1.2k
Gehao Liang China 15 894 0.9× 843 0.9× 127 1.2× 132 1.6× 31 0.4× 29 1.1k
Xiuchong Yu China 18 1.4k 1.4× 1.2k 1.3× 112 1.0× 92 1.1× 115 1.6× 29 1.7k
Wu Sun China 15 784 0.8× 665 0.7× 54 0.5× 77 0.9× 51 0.7× 26 989
Shengchun Wang China 13 713 0.7× 466 0.5× 60 0.5× 98 1.2× 37 0.5× 36 965
Shuiyi Liu China 16 727 0.7× 651 0.7× 65 0.6× 108 1.3× 51 0.7× 23 991

Countries citing papers authored by Kefeng Wang

Since Specialization
Citations

This map shows the geographic impact of Kefeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kefeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kefeng Wang more than expected).

Fields of papers citing papers by Kefeng Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kefeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kefeng Wang. The network helps show where Kefeng Wang may publish in the future.

Co-authorship network of co-authors of Kefeng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Kefeng Wang. A scholar is included among the top collaborators of Kefeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kefeng Wang. Kefeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Yuxin, et al.. (2025). Abnormal expression of CDC25C in NSCLC is influenced by transcriptional and RNA N6‑methyladenosine‑mediated post‑transcriptional regulation. International Journal of Oncology. 66(4). 1–18. 1 indexed citations
2.
Wang, Xia, et al.. (2024). Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy. Biomedicine & Pharmacotherapy. 171. 116152–116152. 5 indexed citations
3.
Liu, Han, et al.. (2024). Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma. Journal of Experimental & Clinical Cancer Research. 43(1). 242–242. 13 indexed citations
4.
Lei, Kai, et al.. (2023). A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/ERK signaling. Cell Death and Disease. 14(6). 346–346. 11 indexed citations
5.
Liu, Han, et al.. (2023). Knowledge mapping and current trends of global research on CRISPR in the field of cancer. Frontiers in Cell and Developmental Biology. 11. 1178221–1178221. 5 indexed citations
6.
Zhao, Quan, et al.. (2023). Knowledge mapping and current trends of Warburg effect in the field of cancer. Frontiers in Oncology. 13. 1264083–1264083. 2 indexed citations
7.
Wang, Yuan, et al.. (2023). Knowledge-map analysis of bladder cancer immunotherapy. Human Vaccines & Immunotherapeutics. 19(3). 2267301–2267301. 4 indexed citations
8.
Lei, Kai, Lin Li, Kexi Wang, et al.. (2023). Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma. Oxidative Medicine and Cellular Longevity. 2023. 1–31. 7 indexed citations
9.
Zhang, Gong, et al.. (2023). Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology. Biomedicine & Pharmacotherapy. 159. 114260–114260. 17 indexed citations
10.
Wang, Xia, et al.. (2022). Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance. Cell Death Discovery. 8(1). 383–383. 59 indexed citations
11.
Li, Ruiming, et al.. (2022). lncRNA PVT1: a novel oncogene in multiple cancers. Cellular & Molecular Biology Letters. 27(1). 84–84. 38 indexed citations
12.
Xu, Jie, et al.. (2022). A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers. Frontiers in Cell and Developmental Biology. 10. 997633–997633. 51 indexed citations
13.
Yang, Jun, Manlong Qi, Xiang Fei, Xia Wang, & Kefeng Wang. (2022). Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer progression by sponging miR-140-3p. Cell Death and Disease. 13(4). 322–322. 50 indexed citations
14.
Yang, Jun, Manlong Qi, Xiang Fei, Xia Wang, & Kefeng Wang. (2021). LncRNA H19: A novel oncogene in multiple cancers. International Journal of Biological Sciences. 17(12). 3188–3208. 97 indexed citations
15.
Yang, Jun, Manlong Qi, Xiang Fei, Xia Wang, & Kefeng Wang. (2021). Long non-coding RNA XIST: a novel oncogene in multiple cancers. Molecular Medicine. 27(1). 159–159. 41 indexed citations
16.
17.
Yang, Jun, Junwen Chen, Si Wu, et al.. (2020). <p>Microarray Expression Profiles and Bioinformatics Analyses Reveal Aberrant Circular RNAs Expression in Bladder Cancer</p>. OncoTargets and Therapy. Volume 13. 10889–10899. 1 indexed citations
18.
Hu, Xueting, Duoguang Wu, Xiaotian He, et al.. (2019). circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Molecular Cancer. 18(1). 160–160. 139 indexed citations
19.
20.
Yang, Hang, Qing Xia, Yong Zou, et al.. (2015). M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1α in human breast cancer cells. Oncology Reports. 34(1). 334–340. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erhu Fang Breakdown of academic impact, for papers by Zerong Cai Breakdown of academic impact, for papers by Gehao Liang Breakdown of academic impact, for papers by Xiuchong Yu Breakdown of academic impact, for papers by Wu Sun Breakdown of academic impact, for papers by Shengchun Wang Breakdown of academic impact, for papers by Shuiyi Liu
Rankless by CCL
2026